Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
暂无分享,去创建一个
K. S. Hall | J. Blay | V. Torri | E. Wardelmann | S. Litière | S. Bonvalot | A. Cesne | H. Joensuu | P. Bruzzi | P. Rutkowski | R. Issels | M. Schlemmer | P. Hohenberger | P. Casali | I. Judson | A. D. Tos | D. Vanel | A. Bertuzzi | S. Bielack | B. Bjerkehagen | I. Boukovinas | P. Dileo | M. Eriksson | A. Fedenko | A. Ferrari | S. Ferrari | H. Gelderblom | R. Grimer | A. Gronchi | R. Haas | K. Hall | J. Martín-Broto | O. Merimsky | M. Montemurro | C. Morosi | P. Picci | I. Ray-Coquard | P. Reichardt | S. Stacchiotti | A. Trama | F. Coevorden | W. V. D. Graaf
[1] J. Coindre,et al. Soft‐tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system , 1984, International journal of cancer.
[2] J. Crowley,et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Cesne,et al. High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] E. Casper,et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Wanebo,et al. Soft tissue sarcoma. , 1997, Medicine and health, Rhode Island.
[6] S. Steinberg,et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] A. Weiss,et al. Therapy of desmoid tumors and fibromatosis using vinorelbine. , 1999, American journal of clinical oncology.
[8] C. Dykewicz. Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] M Bonetti,et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] P. Casali,et al. Low‐dose chemotherapy with methotrexate and vinblastine for patients with advanced aggressive fibromatosis , 2001, Cancer.
[11] A. Davis,et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial , 2002, The Lancet.
[12] Samuel Singer,et al. Histologic Subtype and Margin of Resection Predict Pattern of Recurrence and Survival for Retroperitoneal Liposarcoma , 2003, Annals of surgery.
[13] C. Raut,et al. Retroperitoneal sarcomas: Combined‐modality treatment approaches , 2002, Journal of surgical oncology.
[14] R. Benjamin,et al. Desmoid tumors respond to chemotherapy: defying the dogma in oncology. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Robin L. Jones,et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. , 2007, The Lancet. Oncology.
[16] P. Thall,et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] J. Blay,et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] P. Thall,et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F. Farrokhyar,et al. A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma , 2008, Cancer.
[20] J. Blay,et al. Extra-abdominal primary fibromatosis: Aggressive management could be avoided in a subgroup of patients. , 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[21] M. Franchi,et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). , 2008, European journal of cancer.
[22] J. Blay,et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] J. Blay,et al. Primary retroperitoneal sarcomas: a multivariate analysis of surgical factors associated with local control. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] J. Blay,et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] P. Casali,et al. Response to Sunitinib Malate in Advanced Alveolar Soft Part Sarcoma , 2009, Clinical Cancer Research.
[26] Robin L. Jones,et al. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. , 2009, European journal of cancer.
[27] J. Roth,et al. Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. , 2009, The Annals of thoracic surgery.
[28] J. Thigpen. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study , 2009 .
[29] L. Mariani,et al. Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment , 2009, Annals of Surgical Oncology.
[30] Marc Ladanyi,et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. , 2010, The New England journal of medicine.
[31] L. Mariani,et al. Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma Carried Out at High-Volume Centers is Safe and is Associated With Improved Local Control , 2010, Annals of Surgical Oncology.
[32] C. Antonescu,et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] C. Antonescu,et al. Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor) , 2010, Cancer.
[34] M. van Glabbeke,et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] Peter Wust,et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. , 2010, The Lancet. Oncology.
[36] J. Maurel,et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] P. Ip,et al. Pathology of uterine leiomyosarcomas and smooth muscle tumours of uncertain malignant potential. , 2011, Best practice & research. Clinical obstetrics & gynaecology.
[38] P. Casali,et al. Dermatofibrosarcoma protuberans‐derived fibrosarcoma: Clinical history, biological profile and sensitivity to imatinib , 2011, International journal of cancer.
[39] C. Antonescu,et al. Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis , 2010, Clinical Cancer Research.
[40] A. Eggermont,et al. Long-term results of tumor necrosis factor alpha- and melphalan-based isolated limb perfusion in locally advanced extremity soft tissue sarcomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] B. Quade,et al. Peritoneal Dissemination Complicating Morcellation of Uterine Mesenchymal Neoplasms , 2012, PloS one.
[42] J. Verweij,et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. , 2012, The Lancet. Oncology.
[43] J. Blay,et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.
[44] A. D. Dei Tos,et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] A. D. Dei Tos,et al. Gemcitabine in advanced angiosarcoma: a retrospective case series analysis from the Italian Rare Cancer Network. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] M. van de Rijn,et al. The Clinicopathologic Features of YWHAE-FAM22 Endometrial Stromal Sarcomas: A Histologically High-grade and Clinically Aggressive Tumor , 2012, The American journal of surgical pathology.
[47] L. Mariani,et al. Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[48] J. Blay,et al. Sarcoma: concordance between initial diagnosis and centralized expert review in a population-based study within three European regions. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] A. D. Dei Tos,et al. Sunitinib malate in solitary fibrous tumor (SFT). , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[50] Li-Xuan Qin,et al. A Postoperative Nomogram for Local Recurrence Risk in Extremity Soft Tissue Sarcomas After Limb-Sparing Surgery Without Adjuvant Radiation , 2012, Annals of surgery.
[51] J. Rauh-Hain,et al. Endometrial Stromal Sarcoma: A Systematic Review , 2013, Obstetrics and gynecology.
[52] C. Fletcher,et al. WHO classification of tumours of soft tissue and bone , 2013 .
[53] Robin L. Jones,et al. Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma , 2013, Sarcoma.
[54] J. Wathen,et al. Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma , 2013, Cancer.
[55] David W. Henry,et al. Safety and efficacy of high‐dose tamoxifen and sulindac for desmoid tumor in children: Results of a Children's Oncology Group (COG) Phase II Study , 2013, Pediatric blood & cancer.
[56] S. Steinberg,et al. Cediranib for metastatic alveolar soft part sarcoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] C. Stiller,et al. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project. , 2013, European journal of cancer.
[58] C. Nezhat,et al. Evaluating the risks of electric uterine morcellation. , 2014, JAMA.
[59] C. Mussi,et al. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm-a position paper from the Italian and the French Sarcoma Group. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[60] P. Dileo,et al. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients , 2014, British Journal of Cancer.
[61] T. Group,et al. Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach From the Trans-Atlantic RPS Working Group , 2014, Annals of Surgical Oncology.
[62] K. Rankin,et al. Preoperative Versus Postoperative Radiotherapy in Soft-Tissue Sarcoma of the Limbs: A Randomised Trial , 2014 .
[63] P. Schwartz,et al. Hormonal Therapy for Aggressive Angiomyxoma: A Case Report and Proposed Management Algorithm , 2014, Journal of lower genital tract disease.
[64] U. Mansmann,et al. Effectiveness of Regional Hyperthermia With Chemotherapy for High-Risk Retroperitoneal and Abdominal Soft-Tissue Sarcoma After Complete Surgical Resection: A Subgroup Analysis of a Randomized Phase-III Multicenter Study , 2014, Annals of surgery.
[65] J. Blay,et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. , 2014, The Lancet. Oncology.
[66] S. Steinberg,et al. Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial , 2014, Annals of Surgical Oncology.